These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12307521)

  • 1. Cervical cancer screening.
    Christine BW
    Conn Health Bull; 1974 Jan; 89(1):19-21. PubMed ID: 12307521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer in Connecticut, 1969.
    Christine BW; Flannery JT; Sullivan PD
    Conn Health Bull; 1972 Apr; 86(4):103-14. PubMed ID: 12332971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer in Connecticut, 1970.
    Christine BW; Sullivan PD; Flannery JT
    Conn Health Bull; 1972 Nov; 86(11):345-56. PubMed ID: 12256552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for cervical cancer in Jamaica.
    Fletcher H
    Caribb Health; 1999 Apr; 2(1):9-11. PubMed ID: 12349102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
    Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
    J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive cervical cancer among Hispanic and non-Hispanic women--United States, 1992-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1067-70. PubMed ID: 12500907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women.
    Yang B; Morrell S; Zuo Y; Roder D; Tracey E; Jelfs P
    Cancer Causes Control; 2008 Aug; 19(6):569-76. PubMed ID: 18286380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
    Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
    Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cervical cancer screening program at a rural community of South Africa.
    Hoque M; Hoque E; Kader SB
    East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of cervical cancer in Brazil.
    Pinotti JA; Carvalho JP; Nisida AC
    Arch AIDS Res; 1994; 8(3-4):199-207. PubMed ID: 12318981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cayman Islands: cervical cancer increases.
    Caribb Health; 1999 Jan; 1(4):4. PubMed ID: 12294650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned?
    Perkins RB; Langrish SM; Stern LJ; Figueroa J; Simon CJ
    Trop Med Int Health; 2007 Sep; 12(9):1018-25. PubMed ID: 17875013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA gives final approval to Depo amid concerns over safety, cost and coercion.
    Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):2-3. PubMed ID: 12344620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.
    Sepúlveda C; Prado R
    Cancer Detect Prev; 2005; 29(5):405-11. PubMed ID: 16188399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for breast and cervical cancer in Europe. Hungary.
    Batar I
    Entre Nous Cph Den; 1996 Dec; (34-35):9. PubMed ID: 12222284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000.
    Singh GK; Miller BA; Hankey BF; Edwards BK
    Cancer; 2004 Sep; 101(5):1051-7. PubMed ID: 15329915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
    Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
    J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
    Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
    J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of invasive cervical cancer after three consecutive negative Pap smears.
    Coldman A; Phillips N; Kan L; Matisic J; Benedet L; Towers L
    J Med Screen; 2003; 10(4):196-200. PubMed ID: 14738657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.